Vergelijking

Pasireotid vs. Semax

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

396091-73-9

80714-61-0

Molecuulmassa

1047.21 g/mol

813.92 g/mol

Halfwaardetijd

geen gegevens

0.3 h

Sequentie

geen gegevens

Met-Glu-His-Phe-Pro-Gly-Pro

Werkingsmechanisme

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Semax

Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pasireotid	Semax
Duitsland	Op recept	Niet goedgekeurd
RU	—	Op recept
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Pasireotid

Volledige vermelding →

Semax

Volledige vermelding →

Frequently asked questions

What is the difference between Pasireotid and Semax?: Pasireotid is classified as "Onderzoek (overig)", while Semax is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Semax?: The highest available evidence level is "Humane RCT" for Pasireotid and "Humane studie" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Semax in Germany and the United States?: Duitsland: Pasireotid — Op recept, Semax — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Semax — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Semax

Duitsland

Op recept

Niet goedgekeurd

—

Op recept

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Pasireotid and Semax?

Pasireotid is classified as "Onderzoek (overig)", while Semax is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Semax?

The highest available evidence level is "Humane RCT" for Pasireotid and "Humane studie" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Semax in Germany and the United States?

Duitsland: Pasireotid — Op recept, Semax — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Semax — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.